AKBA
Akebia TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade D from latest DB weights. Momentum 16.4 / Value 65.8
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
16
Value
66
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-28 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $4.40
Why
Momentum16 · Δ7d -
Value66 · Δ7d +0.2
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
16
52% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
66
48% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+1.4
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 16.4 / Value 65.8
Fundamentals (TTM)As of 2026-05-28
Fundamentals (TTM)
As of 2026-05-28
Market Cap
$281.67M
Beta
0.38
Shares Out
265.37M
P/E (TTM) · Derived
-51.0
P/S (TTM)
1.78
P/FCF (TTM)
12.45
Rev YoY
+57.0%
EPS YoY
+102.1%
Gross Margin
+81.9%
Op Margin
+7.9%
Net Debt
$125.87M
Current Ratio
1.94
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology